NCT03204396View on ClinicalTrials.gov

Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues

PHASE2CompletedINTERVENTIONAL
Enrollment

256

Participants

Timeline

Start Date

June 26, 2017

Primary Completion Date

July 30, 2022

Study Completion Date

August 30, 2022

Conditions
Glucagon-like Peptide-1Smoking CessationWeight Change, BodyCraving
Interventions
DRUG

Dulaglutide

Application of Dulaglutide (Trulicity®) 1.5 mg s.c. once weekly for 12 weeks.

DRUG

0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])

Application of 0.5 ml normal saline (0.9% sodium chloride \[0.9% NaCl\]) once weekly for 12 weeks

Trial Locations (1)

4031

Universitätsspital Basel, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT03204396 - Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues | Biotech Hunter | Biotech Hunter